David Sanchez
General Practice · Santa Ana, CANPI 1316162258
Payments from drug & device makers
Across 372 payments — averaging $32.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Amgen$1K
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- Takeda Pharmaceuticals U.S.A., Inc.$791
- Bayer$674
- plus $5K from 30 others
What the payments were for
- Speaking & faculty fees$1251%
- Food & beverage$11,91697%
- Education$1952%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 46 | $2,310 |
| Amgen | 56 | $1,316 |
| Lilly USA, LLC | 46 | $1,252 |
| Novo Nordisk | 58 | $1,215 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $791 |
| Bayer | 16 | $674 |
| Corcept Therapeutics | 16 | $585 |
| Johnson & Johnson | 11 | $496 |
| AbbVie(2 entities) | 16 | $394 |
| GSK | 4 | $373 |
| Amarin Pharma, Inc. | 7 | $318 |
| Vanda Pharmaceuticals Inc. | 10 | $290 |
| Boehringer Ingelheim | 8 | $271 |
| Sanofi-aventis U.S. LLC | 11 | $266 |
| Sumitomo Pharma America, Inc. | 5 | $196 |
| Phathom Pharmaceuticals, Inc. | 2 | $152 |
| Botanix SB Inc | 1 | $150 |
| Stryker | 1 | $150 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $146 |
| Novartis | 7 | $137 |
| Biohaven Pharmaceuticals, Inc. | 2 | $135 |
| Astellas Pharma US Inc | 3 | $118 |
| Daiichi Sankyo Inc. | 3 | $112 |
| Abbott | 3 | $78 |
| Pfizer | 3 | $57 |
| Almatica Pharma LLC | 2 | $37 |
| Recordati_rare_diseases_inc. | 1 | $34 |
| Boston Scientific | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Electromed, Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $22 |
| Seqirus USA Inc | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Gilead | 1 | $15 |
| Cranial Technologies, Inc | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,236 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 439 | $494,293 |
| FarxigaDapagliflozin Propanediol | 267 | $226,116 |
| VascepaIcosapent Ethyl | 181 | $84,175 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 62 | $54,383 |
| Repatha SureclickEvolocumab | 48 | $35,638 |
| Icosapent Ethyl | 194 | $31,856 |
| GemtesaVibegron | 36 | $30,818 |
| MyrbetriqMirabegron | 26 | $23,144 |
| RybelsusSemaglutide | 16 | $19,148 |
| EliquisApixaban | 28 | $17,591 |
| DapagliflozinDapagliflozin Propanediol | 30 | $13,822 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $13,572 |
| MovantikNaloxegol Oxalate | 18 | $10,311 |
| BelsomraSuvorexant | 21 | $9,813 |
| Lidocaine | 43 | $5,285 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $1,252 | $494,293439 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Airsupra | $2,310 | $244,931300 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $266 | $54,38362 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $196 | $30,81836 claims |
| Astellas Pharma US IncMyrbetriq | $118 | $23,14426 claims |
| Novo NordiskRybelsus | $1,215 | $19,14816 claims |
| PfizerEliquis | $57 | $17,59128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.
Other general practice in Santa Ana
- Luis RiveraSanta Ana$216K
- Hessam AazamiCanoga Park$88.4M
- Frederic MollRedwood City$5.7M
- Nathan LiLancaster$5.2M
- Milton McCollSan Jose$4.9M
- Bruce TorkanLos Angeles$3.8M
- Daniel JohnsonPalm Desert$1.5M
- Bradley ChingUpland$1.4M
- Jared AdamsSan Francisco$862K
- Marina GoldGlendale$784K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.